Abstract
Pharmacogenomic technologies can potentially be beneficial to patients and healthcare providers alike. Decision-makers allocating finite healthcare budgets require robust and timely evidence to support the cost-effectiveness of pharmacogenomic technologies. This paper describes the use of the quality adjusted life year (QALY) to inform decision-making drawing on the examples of National Institute for Health and Care Excellence (NICE) technology appraisals of pharmacogenomic technologies in the UK. Importantly, the paper explains two theoretical viewpoints that underpin the two main types of economic analysis: cost benefit analysis and cost-effectiveness analysis. The advantages and disadvantages of QALYs are discussed together with potential options for moving beyond the QALY such as the use of the capability approach and willingness to pay methods. However, the paper concludes that most health economists, as providers of information for societal decision-making, are probably not yet ready to depart from the QALY to inform resource allocation in the context of pharmacogenomic technologies.
Keywords: Cost benefit analysis, cost effectiveness analysis, decision-making, economic evaluation, QALYs, resource allocation.
Current Pharmacogenomics and Personalized Medicine
Title:Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Volume: 11 Issue: 3
Author(s): Katherine Payne and Alexander J. Thompson
Affiliation:
Keywords: Cost benefit analysis, cost effectiveness analysis, decision-making, economic evaluation, QALYs, resource allocation.
Abstract: Pharmacogenomic technologies can potentially be beneficial to patients and healthcare providers alike. Decision-makers allocating finite healthcare budgets require robust and timely evidence to support the cost-effectiveness of pharmacogenomic technologies. This paper describes the use of the quality adjusted life year (QALY) to inform decision-making drawing on the examples of National Institute for Health and Care Excellence (NICE) technology appraisals of pharmacogenomic technologies in the UK. Importantly, the paper explains two theoretical viewpoints that underpin the two main types of economic analysis: cost benefit analysis and cost-effectiveness analysis. The advantages and disadvantages of QALYs are discussed together with potential options for moving beyond the QALY such as the use of the capability approach and willingness to pay methods. However, the paper concludes that most health economists, as providers of information for societal decision-making, are probably not yet ready to depart from the QALY to inform resource allocation in the context of pharmacogenomic technologies.
Export Options
About this article
Cite this article as:
Payne Katherine and Thompson J. Alexander, Economics of Pharmacogenomics: Rethinking Beyond QALYs?, Current Pharmacogenomics and Personalized Medicine 2013; 11 (3) . https://dx.doi.org/10.2174/18756921113119990001
DOI https://dx.doi.org/10.2174/18756921113119990001 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy
Current Cancer Drug Targets New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Total Synthesis and Bioactivity of ent-homospisulosine and N,O-diacetylhomoclavaminol A
Current Organic Chemistry Development of Radicicol Analogues
Current Cancer Drug Targets Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Foamy Virus Vectors: An Awaited Alternative to Gammaretro- and Lentiviral Vectors
Current Gene Therapy Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers
Mini-Reviews in Medicinal Chemistry The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review
Current Drug Targets Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Meet Our Editorial Board Member
Current Stem Cell Research & Therapy In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Naturally Occurring δ-Hydroxy-γ-Lactones: Muricatacins and Related Compounds
Current Organic Chemistry The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry